Literature DB >> 30768797

Hyperprogression with immunotherapy: Is it real?

Sanjay Popat1,2,3.   

Abstract

Keywords:  NSCLC; checkpoint inhibitor; hyperprogression; immunotherapy; progression

Year:  2019        PMID： 30768797     DOI： 10.1002/cncr.31997

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  9 in total

Review 1.  Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.

Authors:  Steven G Gray
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

Review 2.  Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.

Authors:  Miaozhen Lin; Ben G L Vanneste; Qiwen Yu; Zebin Chen; Jiayu Peng; Xiuyu Cai
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors.

Authors:  Saro Kasparian; Cesar Gentille; Ethan Burns; Eric H Bernicker
Journal:  JTO Clin Res Rep       Date:  2020-02-22

4.  Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.

Authors:  Dukagjin M Blakaj; Marcelo Bonomi; Majd Issa; Brett G Klamer; Nikol Mladkova; Georgios I Laliotis; Vidhya Karivedu; Priyanka Bhateja; Chase Byington; Khaled Dibs; Xueliang Pan; Arnab Chakravarti; John Grecula; Sachin R Jhawar; Darrion Mitchell; Sujith Baliga; Matthew Old; Ricardo L Carrau; James W Rocco
Journal:  BMC Cancer       Date:  2022-07-14       Impact factor: 4.638

5.  Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor.

Authors:  Daniela R Montagna; Alejandra Duarte; Paula Chiarella; Bárbara Rearte; Oscar D Bustuoabad; Mónica Vermeulen; Raúl A Ruggiero
Journal:  BMC Cancer       Date:  2022-08-03       Impact factor: 4.638

Review 6.  Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.

Authors:  Hongjing Zang; Jinwu Peng; Hongmei Zheng; Songqing Fan
Journal:  Front Oncol       Date:  2020-04-29       Impact factor: 6.244

7.  Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Authors:  Jacob J Adashek; Shumei Kato; Roberto Ferrara; Giuseppe Lo Russo; Razelle Kurzrock
Journal:  Oncologist       Date:  2019-11-20

8.  Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.

Authors:  Lei Wu; Wen Quan; Qiong Luo; Ying Pan; Dongxu Peng; Guihai Zhang
Journal:  Front Mol Biosci       Date:  2020-09-24

Review 9.  Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.

Authors:  Steven G Gray; Luciano Mutti
Journal:  Transl Lung Cancer Res       Date:  2020-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.